Use of Nevirapine to Reduce Mother-To-Child Transmission of HIV (Mtct) (Electronic book text)

A recent early report that a single dose of Nevirapine given to HIV-infected women during labour to reduce the risk of mother-to-child transmission (MTCT) of HIV can lead to the selection of Nevirapine (NVP)-resistant virus at 6-weeks in the mother does not warrant exclusion of NVP from pilot MTCT-prevention programmes or research studies. Further information on the safety and effectiveness of NVP is required before recommendations on wide-scale use of NVP can be made.